Overview
Gameto is a clinical-stage biotechnology company developing stem cell-derived therapies for reproductive health using proprietary cell engineering technology. The company creates engineered ovarian support cells derived from induced pluripotent stem cells to enable egg maturation outside the body, substantially reducing the duration and hormonal burden of traditional in vitro fertilization protocols. Gameto's platform addresses multiple conditions affecting women's reproductive health, including infertility, menopause, and ovarian disease. The company's lead program, Fertilo, is currently in Phase 3 clinical trials in the United States and has facilitated multiple healthy births in countries where it has received regulatory approval.